Polypid Ltd (PYPD) Stock Price, Quote & News

Company Profile

PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in precl...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 7 4719 5700

Website: www.polypid.com

Address:

18 Hasivim Street, Petah Tikva, Israel

lelXYpics May. 1 at 11:16 PM

$PYPD volume dry out for institutional investors. Only hard-working retailers can nibble in. IMHO: Volume, at 100Ks/daily will open up at SP > $10 Most likely when the partner is secured.

0 · Reply

TheSuper May. 1 at 10:15 PM

$PYPD added today. Plan to add more next week.

0 · Reply

YoBee May. 1 at 5:33 PM

$PYPD Today is like practice for a halt. 😂

0 · Reply

Finnish_boy May. 1 at 12:10 PM

$PYPD 1 week closer to US partner news.. next week we should have earnings date press release.

0 · Reply

Finnish_boy Apr. 29 at 2:43 PM

$PYPD I wanted to misread that management meant the start of the rolling NDA submission, but they probably mean the finalization, which will happen late May / early June, at the latest in June, according to guidance.

0 · Reply

Finnish_boy Apr. 29 at 1:07 PM

$PYPD I listened once again management's comments about timing of US partnership. It sounds like they told that around when they do the final submission. I think we are talking about the submission early June. I think they will announce US partner in H2 May, just before Q1 earnings. I have misread comments. Sorry for that.

0 · Reply

Finnish_boy Apr. 29 at 12:37 PM

$PYPD Looks like Q1 earnings a week or two later than in previous years. They delayed those due to US partnership. US partnership news in May locked🤑lets go

0 · Reply

Finnish_boy Apr. 29 at 12:12 AM

$PYPD And if you want share price up, ask someone to write article. It would be bigger catalyst than US partner lol. It's possible that they announce US partner and stock up only 20-30% an slowly going up until FDA approval. You need patience on this stock when nobody follow this. Market pricing doesnt work here.

1 · Reply

Finnish_boy Apr. 29 at 12:07 AM

$PYPD And there is no hurry from PYPD side when there are millions in the bank, runaway until Q4 or something, and value of program ticking up when regulatory process is advancing. There are also many interest parties to buy rights. PYPD is in sweet spot. You want it takes longer. The deal value is ticking up every week.

0 · Reply

Finnish_boy Apr. 29 at 12:03 AM

$PYPD I bought more today. Fireworks can start anytime now. My best guess is 6th May but at least we learn more on Q1 earnings in 2 weeks.

0 · Reply

PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting

Apr 13, 2026, 9:15 AM EDT - 19 days ago

PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026

Mar 31, 2026, 8:30 AM EDT - 4 weeks ago

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

Mar 17, 2026, 8:30 AM EDT - 6 weeks ago

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application

Mar 10, 2026, 1:40 PM EDT - 7 weeks ago

PolyPid Transcript: The Citizens Life Sciences Conference 2026

Feb 25, 2026, 8:35 AM EST - 2 months ago

PolyPid Announces Participation in Upcoming Investor Conferences

Feb 11, 2026, 8:30 AM EST - 2 months ago

PolyPid Earnings Call Transcript: Q4 2025

Feb 11, 2026, 7:30 AM EST - 2 months ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Jan 28, 2026, 8:00 AM EST - 3 months ago

PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

Jan 15, 2026, 10:30 AM EST - 3 months ago

PolyPid Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit

Dec 16, 2025, 8:30 AM EST - 4 months ago

PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

Dec 10, 2025, 11:30 AM EST - 5 months ago

PolyPid Transcript: KOL Event

Dec 3, 2025, 8:30 AM EST - 5 months ago

PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

Nov 25, 2025, 8:30 AM EST - 5 months ago

PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025

Nov 12, 2025, 8:30 AM EST - 6 months ago

PolyPid Earnings Call Transcript: Q3 2025

Nov 12, 2025, 7:30 AM EST - 6 months ago

PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 8:30 AM EST - 6 months ago

PolyPid's D-PLEX₁₀₀ Wins BioTech Breakthrough Award for "Therapeutics Solution of the Year"

Oct 29, 2025, 8:30 AM EDT - 6 months ago

PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

Sep 30, 2025, 12:30 PM EDT - 7 months ago

PolyPid Transcript: Lytham Partners Fall 2025 Investor Conference

Sep 30, 2025, 8:45 AM EDT - 7 months ago

PolyPid to Present Its Positive Phase 3 SHIELD II Topline Results at the 2025 American College of Surgeons Clinical Congress

Sep 17, 2025, 8:44 AM EDT - 8 months ago

PolyPid to Present at Lytham Partners Fall 2025 Investor Conference and Participate in 4th Annual ROTH Healthcare Opportunities Conference

Sep 16, 2025, 8:30 AM EDT - 8 months ago

PolyPid Successfully Completes Israeli Ministry of Health GMP Inspection, Advancing Towards Commercial Manufacturing Readiness for D-PLEX₁₀₀

Sep 3, 2025, 8:30 AM EDT - 8 months ago

PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Sep 2, 2025, 8:30 AM EDT - 8 months ago

PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

Aug 13, 2025, 8:30 AM EDT - 9 months ago

PolyPid Earnings Call Transcript: Q2 2025

Aug 13, 2025, 7:30 AM EDT - 9 months ago

PolyPid Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 12, 2025, 8:00 AM EDT - 9 months ago

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

Jul 30, 2025, 8:00 AM EDT - 9 months ago

PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025

Jul 15, 2025, 8:00 AM EDT - 10 months ago

PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market

Jun 16, 2025, 7:20 PM EDT - 11 months ago

PolyPid Secures $26.7 Million Through Warrant Exercise Following Successful SHIELD II Phase 3 Trial Results

Jun 11, 2025, 9:42 AM EDT - 11 months ago

PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 11, 2025, 9:40 AM EDT - 11 months ago

PESG Research Update: PolyPid SHIELD's II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

Jun 9, 2025, 8:54 AM EDT - 11 months ago

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript

Jun 9, 2025, 8:30 AM EDT - 11 months ago

PolyPid Transcript: Status Update

Jun 9, 2025, 7:30 AM EDT - 11 months ago

PolyPid Announces Positive Topline Results from Phase 3 SHIELD II Trial: D-PLEX₁₀₀ Demonstrated Significant Reduction in Surgical Site Infections and Successfully Met Primary and All Key Secondary Endpoints

Jun 6, 2025, 4:05 PM EDT - 11 months ago

PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

May 30, 2025, 10:12 AM EDT - 1 year ago

PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid's D-PLEX100 Approaches Critical Phase 3 Data Readout

May 29, 2025, 10:15 AM EDT - 1 year ago

PolyPid Transcript: Lytham Partners Spring 2025 Investor Conference

May 20, 2025, 7:00 AM EDT - 1 year ago

PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

May 14, 2025, 8:30 AM EDT - 1 year ago

PolyPid Earnings Call Transcript: Q1 2025

May 14, 2025, 7:00 AM EDT - 1 year ago

PolyPid Provides Corporate Update and Reports First Quarter 2025 Financial Results

Apr 29, 2025, 7:00 AM EDT - 1 year ago

PolyPid to Report First Quarter 2025 Financial Results and Operational Highlights on May 14, 2025

Apr 22, 2025, 7:00 AM EDT - 1 year ago

PolyPid to Participate in The Citizens Life Sciences Conference

Mar 11, 2025, 7:00 AM EDT - 1 year ago

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Mar 3, 2025, 7:00 AM EST - 1 year ago

PolyPid to Participate in the 37th Annual ROTH Conference

Feb 12, 2025, 11:20 AM EST - 1 year ago

PolyPid Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Feb 12, 2025, 8:30 AM EST - 1 year ago

PolyPid Earnings Call Transcript: Q4 2024

Feb 12, 2025, 7:00 AM EST - 1 year ago

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results

Jan 30, 2025, 7:00 AM EST - 1 year ago

PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 29, 2025, 7:00 AM EST - 1 year ago

PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025

Dec 26, 2024, 10:31 AM EST - 1 year ago

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

KMPR ACVA AVXL

Dec 23, 2024, 7:22 PM EST - 1 year ago

PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million

Dec 11, 2024, 7:00 AM EST - 1 year ago

PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy

Nov 29, 2024, 1:05 PM EST - 1 year ago

PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance

Nov 14, 2024, 8:30 AM EST - 1 year ago

PolyPid Transcript: 2024 Sidoti Virtual Micro-Cap Conference

Nov 13, 2024, 8:30 AM EST - 1 year ago

PolyPid Earnings Call Transcript: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference

Oct 30, 2024, 8:00 AM EDT - 1 year ago

PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024

Oct 21, 2024, 7:00 AM EDT - 1 year ago

PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery

Oct 1, 2024, 7:00 AM EDT - 1 year ago

PolyPid Announces Last Patient In for Planned Unblinded Interim Analysis in the Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Sep 3, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Participate in Three Upcoming Fall Investor Conferences

Aug 14, 2024, 8:30 AM EDT - 1 year ago

PolyPid Earnings Call Transcript: Q2 2024

Aug 1, 2024, 8:31 PM EDT - 1 year ago

PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds

Jul 31, 2024, 7:00 AM EDT - 1 year ago

PolyPid to Report Second Quarter 2024 Financial Results and Operational Highlights on August 14, 2024

Jun 10, 2024, 7:00 AM EDT - 2 years ago

PolyPid to Host Virtual KOL Event on June 17, 2024, and Provide an Update on the Company's Ongoing D-PLEX₁₀₀ Phase 3 Trial

May 8, 2024, 8:30 AM EDT - 2 years ago

PolyPid Earnings Call Transcript: Q1 2024

Nov 8, 2023, 8:30 AM EST - 2 years ago

PolyPid Earnings Call Transcript: Q3 2023

Aug 9, 2023, 8:30 AM EDT - 2 years ago

PolyPid Earnings Call Transcript: Q2 2023

May 10, 2023, 8:30 AM EDT - 3 years ago

PolyPid Earnings Call Transcript: Q1 2023

Feb 8, 2023, 8:30 AM EST - 3 years ago

PolyPid Earnings Call Transcript: Q4 2022

Nov 9, 2022, 8:30 AM EST - 3 years ago

PolyPid Earnings Call Transcript: Q3 2022

Aug 10, 2022, 8:30 AM EDT - 4 years ago

PolyPid Earnings Call Transcript: Q2 2022

lelXYpics May. 1 at 11:16 PM

$PYPD volume dry out for institutional investors. Only hard-working retailers can nibble in. IMHO: Volume, at 100Ks/daily will open up at SP > $10 Most likely when the partner is secured.

0 · Reply

TheSuper May. 1 at 10:15 PM

$PYPD added today. Plan to add more next week.

0 · Reply

YoBee May. 1 at 5:33 PM

$PYPD Today is like practice for a halt. 😂

0 · Reply

Finnish_boy May. 1 at 12:10 PM

$PYPD 1 week closer to US partner news.. next week we should have earnings date press release.

0 · Reply

Finnish_boy Apr. 29 at 2:43 PM

0 · Reply

Finnish_boy Apr. 29 at 1:07 PM

0 · Reply

Finnish_boy Apr. 29 at 12:37 PM

$PYPD Looks like Q1 earnings a week or two later than in previous years. They delayed those due to US partnership. US partnership news in May locked🤑lets go

0 · Reply

Finnish_boy Apr. 29 at 12:12 AM

1 · Reply

Finnish_boy Apr. 29 at 12:07 AM

0 · Reply

Finnish_boy Apr. 29 at 12:03 AM

$PYPD I bought more today. Fireworks can start anytime now. My best guess is 6th May but at least we learn more on Q1 earnings in 2 weeks.

0 · Reply

Finnish_boy Apr. 29 at 12:01 AM

$PYPD Before Story joined them they told to inform partner at the start of 2026. After that, they have had more potential partners in discussion. It's called bidding process. It takes time. The longer it takes, the more bullish the deal will be. Be patient guys. You have no hurry. Wait max 2 months and buy a plane or boat with your cute PYPD gains.🤑

0 · Reply

PaulWalter Apr. 28 at 9:47 PM

$PYPD Where’s the partnership? They’ve had years. I’m telling you, these guys couldn’t close an envelope.

0 · Reply

focafoca99 Apr. 28 at 6:42 PM

$PYPD plans to present SHIELD II Phase 3 data, so this one is mainly a scientific meeting and data-presentation notice.

0 · Reply

Morgan8758 Apr. 28 at 1:28 PM

$PYPD anyone have opinion when they’d announce partnership

3 · Reply

Finnish_boy Apr. 28 at 1:12 PM

$PYPD YES.

0 · Reply

Finnish_boy Apr. 28 at 1:10 PM

$PYPD They put all the possible clinical data out, inform earnings date, and heading into Q1 earnings call... gather attention... and the BOOM. US partnership.

0 · Reply

WallStWireAds Apr. 28 at 12:31 PM

$PYPD https://www.globenewswire.com/news-release/2026/04/28/3282664/0/en/PolyPid-to-Present-Data-from-SHIELD-II-Phase-3-Trial-Demonstrating

0 · Reply

Finnish_boy Apr. 27 at 8:18 PM

$PYPD $10 within a month. Double very soon. 100% gains. Trust me. I promise.

0 · Reply

Finnish_boy Apr. 24 at 10:22 PM

$PYPD I have lost tens of thousands (missed gains with my other positions) when holding oversized position here. It is what it is. I thought at first they announce US partner in January, then March, and then April, and now May. And it can be later also😂 but luckily earnings call in 3 weeks🤑US partner in 2 weeks maybe!

2 · Reply

WallStWireAds Apr. 23 at 10:38 PM

$PYPD https://ionanalytics.com/insights/mergermarket/polypid-explores-licensing-partnerships-alongside-the-sage-group-ceo/

1 · Reply

dirkflute Apr. 23 at 2:28 PM

$PYPD OK I will take a nibble here.

0 · Reply

trademama87 Apr. 23 at 1:18 PM

$PYPD

0 · Reply

Market Cap	85.87M
Revenue (ttm)	0.00
Net Income (ttm)	-34.17M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.09

Volume	13,400
Avg Vol	52,116
Day's Range	N/A - N/A
Shares Out	19.08M
Stochastic %K	31%
Beta	1.45
Analysts	Strong Sell
Price Target	$12.25